ChiCTR2500098871 版本V1.0 版本创建时间2025/03/14 14:17:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500098871 

最近更新日期:

Date of Last Refreshed on:

2025-03-14 14:17:05 

注册时间:

Date of Registration:

2025-03-14 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

血液肿瘤患者PICC堵管的多因素分析

Public title:

Multivariate Analysis of PICC Occlusion in Patients with Hematological Malignancies

注册题目简写:

English Acronym:

研究课题的正式科学名称:

血液肿瘤患者PICC堵管的多因素分析

Scientific title:

Multivariate Analysis of PICC Occlusion in Patients with Hematological Malignancies

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

武香玲 

研究负责人:

武香玲 

Applicant:

Wu Xiangling 

Study leader:

Wu Xiangling 

申请注册联系人电话:

Applicant telephone:

+86 158 1008 1210

研究负责人电话:

Study leader's telephone:

+86 158 1008 1210

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

heiantianshi1468@sina.com

研究负责人电子邮件:

Study leader's E-mail:

heiantianshi1468@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区西直门南大街11号

研究负责人通讯地址:

北京市西城区西直门南大街11号

Applicant address:

No. 11 South West Zhimen Road, Xicheng District, Beijing, China

Study leader's address:

No. 11 South West Zhimen Road, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学人民医院

Applicant's institution:

Peking University People's Hospital

研究负责人所在单位:

北京大学人民医院

Affiliation of the Leader:

Peking University People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022PHB124-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学人民医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Peking University People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-02 00:00:00

伦理委员会联系人:

母双

Contact Name of the ethic committee:

Mu Shuang

伦理委员会联系地址:

北京市西城区西直门南大街11号, 北京大学人民医院伦理审查委员会

Contact Address of the ethic committee:

Ethics Review Committee of Peking University People's Hospital,No. 11 South West Zhimen Road, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8832 4516

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学人民医院

Primary sponsor:

Peking University People's Hospital

研究实施负责(组长)单位地址:

北京市西城区西直门南大街11号, 18A

Primary sponsor's address:

18A,No. 11 South West Zhimen Road, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

具体地址:

北京市西城区西直门南大街11号, 18A

Institution
hospital:

Peking University People's Hospital

Address:

18A,No. 11 South West Zhimen Road, Xicheng District, Beijing, China

经费或物资来源:

北京大学人民医院研究与发展基金(科研)

Source(s) of funding:

Research and Development Fund of Peking University People's Hospital

Target disease:

Hematological malignancy

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1.调查血液肿瘤患者PICC堵管的发生率 2.分析血液肿瘤患者PICC堵管的影响因素  

Objectives of Study:

1. Investigate the incidence of PICC tube blockage in patients with hematologic tumors 2. The influencing factors of PICC tube blocking in patients with blood tumors were analyzed

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)血液肿瘤留置PICC患者 2)发生PICC堵管的患者

Inclusion criteria

1) PICC patients with blood tumors 2) Patients with PICC tube blockag

排除标准:

非住院期间发生PICC堵管的患者

Exclusion criteria:

Patients with PICC occlusion during non-hospitalization

研究实施时间:

Study execute time:

From 2021-06-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-02 00:00:00 To 2023-04-30 00:00:00  

干预措施:

Interventions:

组别:

堵管组

样本量:

22

Group:

Tube blockag group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

88

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学人民医院 

单位级别:

三甲 

Institution
hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

性别

指标类型:

主要指标

Outcome:

Sex

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

主要指标

Outcome:

Age

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活自理能力

指标类型:

主要指标

Outcome:

Activities of Daily Living, ADL

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诊断

指标类型:

主要指标

Outcome:

Diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨髓形态中原始细胞比例

指标类型:

主要指标

Outcome:

Proportion of original cells in bone marrow morphology

Type:

Primary indicator

测量时间点:

proportion of original cells in peripheral blood

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

外周血中原始细胞比例

指标类型:

主要指标

Outcome:

Proportion of original cells in peripheral blood

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管类型

指标类型:

主要指标

Outcome:

Catheter type

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管体外长度

指标类型:

主要指标

Outcome:

Catheter length in vitro

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

主要指标

Outcome:

Coagulation function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

置管后发热天数

指标类型:

主要指标

Outcome:

Days of fever after catheterization

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽天数

指标类型:

主要指标

Outcome:

Days of cough

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

使用抗生素天数

指标类型:

主要指标

Outcome:

Days of antibiotic use

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

静脉高营养天数

指标类型:

主要指标

Outcome:

Days of intravenous high nutrition

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血制品次数

指标类型:

主要指标

Outcome:

Times of blood products were compared

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

https://ngdc.cncb.ac.cn/gsub/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

https://ngdc.cncb.ac.cn/gsub/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form:CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-03-14 14:17:05